bio sketch column
Stuart L Schreiber, PhD is the director of the Center for the Science of Therapeutics and one of four founders of the Broad Institute, where he is a Howard Hughes Medical Institute Investigator. He is also the Morris Loeb Professor of Chemistry and Chemical Biology at Harvard University, and a member of the National Academy of Sciences. Dr. Schreiber’s research integrates chemical biology and human biology to advance the science of therapeutics. He is known for having developed systematic ways to explore biology, especially disease biology, using small molecules, and for his role in the development of the field of chemical biology. He discovered principles that underlie information transfer and storage in cells, specifically discoveries relating to signaling by the phosphatase calcineurin and kinase mTOR (demonstrating for the first time that drugs can result from the targeting of protein kinases and protein phosphatases), gene regulation by chromatin-modifying histone deacetylases, small-molecule dimerizers that activate cellular processes by enforced proximity, and small-molecule probes of challenging targets and processes (e.g., transcription factors, oncogenes, protein-protein interactions, transdifferentiation) that relate to human disease. His work has contributed to diversity-oriented synthesis (DOS) and discovery-based small-molecule screening in an open data-sharing environment. His research has been reported in over 500 publications (H-index = 133). Schreiber extended chemical biology principles to medicine by participating in the founding of several biotech companies, including Vertex Pharmaceuticals (fosamprenavir/Lexiva; telaprevir/Incivek; ivacaftor/Kalydeco), ARIAD Pharmaceuticals (ponatinib/Iclusig; AP26113; ridaforolimus; AP1903), Infinity Pharmaceuticals (retaspimycin; duvelisib), Forma Therapeutics and H3 Biomedicine.